For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Valo Health, Inc.

USPTO Granted Patents = 31

EPO Patents = 2

Trademarks = 9

Forward Citations = 26

Loading Chart...

Loading Chart...

53 inventors (with patents filed for the assignee):

Xiaozhang Zheng (20 out of 107 patents)

Pui Yee Ng (18 out of 79 patents)

David R Lancia, Jr (16 out of 113 patents)

4. Bingsong Han (15 out of 75 patents)

5. Aleksandra Rudnitskaya (13 out of 53 patents)

6. Jennifer R Thomason (11 out of 46 patents)

7. Mary-Margaret Zablocki (11 out of 48 patents)

8. Cuixian Liu (10 out of 55 patents)

9. Kenneth W Bair (10 out of 82 patents)

10. Matthew W Martin (10 out of 74 patents)

11. Zhongguo Wang (7 out of 57 patents)

12. Alexandre Joseph Buckmelter (7 out of 54 patents)

13. Stephanos Ioannidis (6 out of 39 patents)

14. Justin Andrew Caravella (5 out of 47 patents)

15. Nicholas Barczak (5 out of 15 patents)

31 patents: Sort by Forward Citations

1. 12479807 - METHODS USING HDAC11 INHIBITORS (2025-11-25),

2. 12336981 - Compounds and compositions for the inhibition of NAMPT (2025-06-24),

3. 12304904 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors (2025-05-20),

4. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2025-04-01),

5. 12252490 - Inhibiting deubiquitinase USP25 and USP28 (2025-03-18),

6. 12213969 - 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors (2025-02-04),

7. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors (2024-12-10),

8. 12116362 - Monocyclic compounds useful as GPR120 modulators (2024-10-15),

9. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

10. 11919891 - Bicyclic compounds useful as GPR120 modulators (2024-03-05),

11. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2024-03-05),

12. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2024-02-06),

13. 11795171 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2023-10-24),

14. 11739071 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors (2023-08-29),

15. 11730721 - 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors (2023-08-22),

Valo Health is a technology company on a mission to accelerate the drug discovery and development process. Leveraging AI, machine learning, and other advanced technologies, Valo Health aims to transform the pharmaceutical industry, enabling more efficient and effective ways to discover and develop life-saving medicines. With a multidisciplinary team of scientists, engineers, and data experts, Valo Health is revolutionizing the way new drugs are found and created.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

31 Patents

#80 in Boston, MA

#624 in Massachusetts

#10,575 in US

#20,669 in the World

Boston, MA, United States of America

Valo Health, Inc.

Forward Citations = 26

53 inventors:

Xiaozhang Zheng (20 out of 107 patents)

Pui Yee Ng (18 out of 79 patents)

David R Lancia, Jr (16 out of 113 patents)

4. Bingsong Han (15 out of 75 patents)

5. Aleksandra Rudnitskaya (13 out of 53 patents)

Please report any incorrect information to support@idiyas.com

Loading…